GlassScriptPhysician profile
Tarun M Kumar
NPI 1467613588
$2,695.91
in general payments reported to CMS, 2019-2025
27 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $98.10 · 2021: $187 · 2022: $339 · 2023: $459 · 2024: $496 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $402.78 | 2019-2024 | Dupixent |
| Genzyme Corporation | $390.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $337.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $319.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $177.39 | 2019-2025 | |
| Kaleo, INC. | $160.63 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $131.11 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $129.10 | 2022-2025 | Fasenra, Airsupra |
| Amgen INC. | $91.68 | 2022-2024 | Tezspire |
| Pfizer INC. | $85.72 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $64.26 | 2023 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.86 | 2021-2022 | |
| Galderma Laboratories, L.P. | $34.91 | 2025 | Nemluvio |
| Genentech, INC. | $33.25 | 2022 | |
| Abbvie INC. | $29.18 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $27.47 | 2024 | Palforzia |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.27 | 2019-2020 | |
| Octapharma USA, INC. | $25.67 | 2024 | Cutaquig |
| Dermavant Sciences, INC. | $25.05 | 2023 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $20.64 | 2022 | |
| Shire North American Group INC | $19.17 | 2019 | |
| Jubilant Hollisterstier LLC | $18.31 | 2019 | |
| Grifols USA, LLC | $18.07 | 2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $16.59 | 2025 | Neffy |
| Blueprint Medicines Corporation | $16.05 | 2022 | |
| Organon LLC | $5.57 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.